Multimodal cancer immunotherapy is a combination of cancer immunotherapies used to treat cancer in patients. T cell receptor diversity is used as a component of a method to treat cancer involving cancer therapy, including multimodal cancer immunotherapy.

Multimodal cancer immunotherapy is a combination of cancer immunotherapies used to treat cancer in patients. T cell receptor diversity is used as a component of a method to treat cancer involving cancer therapy, including multimodal cancer immunotherapy.

Described herein are compositions capable of targeting CaMKKβ and/or AMPK alpha and formulations thereof. Also described herein are methods of using the compositions and formulations thereof. In some embodiments, the compositions capable of targeting CaMKKβ and/or AMPK alpha and formulations thereof can prevent or treat outer hair cell loss, such as that which can occur as a result of auditory or chemical insult. In some embodiments, the compositions capable of targeting CaMKKβ and/or AMPK alpha and formulations thereof can treat or prevent acquired hearing loss.

Described herein are compositions capable of targeting CaMKKβ and/or AMPK alpha and formulations thereof. Also described herein are methods of using the compositions and formulations thereof. In some embodiments, the compositions capable of targeting CaMKKβ and/or AMPK alpha and formulations thereof can prevent or treat outer hair cell loss, such as that which can occur as a result of auditory or chemical insult. In some embodiments, the compositions capable of targeting CaMKKβ and/or AMPK alpha and formulations thereof can treat or prevent acquired hearing loss.

The present invention provides agents having efficacy against viruses, allergens, bacteria and odorants, materials including such agents, and methods for producing the agents. An agent according to an embodiment of the present invention includes titanium dioxide particles having low photocatalytic activity, and metal ions of at least one metal selected from gold, silver, platinum and copper that are adsorbed to the surface of the titanium dioxide particles. The agent may further include hydroxyapatite particles, and the metal ions may be adsorbed also to the surface of the hydroxyapatite. The metal ions may be at least partially present in the form of at least one of an oxide of the metal, a hydroxide of the metal, and the elemental metal.

The present invention provides agents having efficacy against viruses, allergens, bacteria and odorants, materials including such agents, and methods for producing the agents. An agent according to an embodiment of the present invention includes titanium dioxide particles having low photocatalytic activity, and metal ions of at least one metal selected from gold, silver, platinum and copper that are adsorbed to the surface of the titanium dioxide particles. The agent may further include hydroxyapatite particles, and the metal ions may be adsorbed also to the surface of the hydroxyapatite. The metal ions may be at least partially present in the form of at least one of an oxide of the metal, a hydroxide of the metal, and the elemental metal.

The present invention relates to a human AMHRII-binding agent for its use for preventing or treating a lung cancer, and especially a non-small call lung cancer (NSCLC), and even more especially a NSCLC selected in a group comprising epidermoid NSCLC, adenocarcinoma NSCLC, large cells NSCLC and squamous cell carcinoma NSCLC and neuroendocrine NSCLC.

The present invention relates to a human AMHRII-binding agent for its use for preventing or treating a lung cancer, and especially a non-small call lung cancer (NSCLC), and even more especially a NSCLC selected in a group comprising epidermoid NSCLC, adenocarcinoma NSCLC, large cells NSCLC and squamous cell carcinoma NSCLC and neuroendocrine NSCLC.

Genetically programmed microorganisms, such as bacteria or virus, pharmaceutical compositions thereof, and methods of modulating and treating cancers are disclosed.

The specification relates to osimertinib or a pharmaceutically acceptable salt thereof for use in the treatment of patients with locally advanced unresectable epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (Stage III)), and in particular to the treatment of patients whose disease has not progressed following definitive platinum-based chemoradiation therapy.